Isis And Bayer Partner On Injectable Anticoagulant

Isis will receive $100 million up front from Bayer in exchange for rights to develop and commercialize ISIS-FXI for the prevention of thrombosis; Bayer will study the drug in patients for whom currently available anticoagulants may not be used.